top646 online games
By LARRY NEUMEISTER, Associated Press NEW YORK (AP) — In an angry outburst in a New York courtroom, Rudy Giuliani accused a judge Tuesday of making wrong assumptions about him as he tries to comply with an order requiring him to turn over most of his assets to two election poll workers who won a libel case against him. U.S. District Judge Lewis J. Liman responded by saying he’s not going to let the former New York City mayor and onetime presidential candidate blurt things out anymore in court unless he’s a sworn witness. The interruption to an otherwise routine pretrial hearing in Manhattan came as the judge questioned Giuliani’s lawyer about why Giuliani has not yet provided the title to a car he has relinquished in his effort to satisfy a $148 million defamation judgment won by two former Georgia election workers. “Your client was the U.S. attorney for this district,” the judge said, referring to Giuliani’s years in the 1980s as the head of the federal prosecutor’s office in the Southern District of New York, as he suggested it was hard to believe that Giuliani was incapable of getting a duplicate title to the car. Related Articles Giuliani learned forward and began speaking into a microphone, telling the judge he had applied for a duplicate copy of the car’s title but that it had not yet arrived. “The implication I’ve been not diligent about it is totally incorrect,” Giuliani said in a scolding tone. “The implication you make is against me and every implication against me is wrong.” Giuliani went on: “I’m not impoverished. Everything I have is tied up. I don’t have a car. I don’t have a credit card. I don’t have cash. I can’t get to bank accounts that truly would be mine because they have put ... stop orders on, for example, my Social Security account, which they have no right to do.” Liman responded by warning defense lawyers that the next time Giuliani interrupts a hearing, “he’s not going to be permitted to speak and the court will take action.” The judge said Giuliani could either choose to represent himself or let lawyers do so, but “you can’t have hybrid representation.” If Giuliani wants to speak in court again, he can be put on the witness stand and be sworn as a witness, Liman added. The exchange came at a hearing in which the judge refused to delay a Jan. 16 trial over the disposition of Giuliani’s Florida residence and World Series rings. Those are two sets of assets that Giuliani is trying to shield from confiscation as part of Liman’s order to turn over many prized possessions to the poll workers. Earlier in the proceeding, defense attorney Joseph M. Cammarata asked Liman to delay the trial, which will be heard without a jury, for a month because of Giuliani’s “involvement” in inauguration planning for President-elect Donald Trump. “My client regularly consults and deals directly with President-elect Trump on issues that are taking place as the incoming administration is afoot as well as (the) inauguration,” Cammarata said. “My client wants to exercise his political right to be there.” The judge turned down the request, saying Giuliani’s “social calendar” was not a reason to postpone the trial. Giuliani, who once served as Trump’s personal attorney, was found liable last year for defaming two Georgia poll workers by falsely accusing them of tampering with ballots during the 2020 presidential election. The women said they faced death threats after Giuliani falsely claimed they sneaked in ballots in suitcases, counted ballots multiple times and tampered with voting machines.JDF soldier arrested in $47-m phishing scam
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis CLLS (the "Company"), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million ("Tranche C") under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the "EIB) on December 28, 2022 (the "Finance Contract"). With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22. As a condition to the disbursement of Tranche C the Company issued 611,426 warrants to the benefit of the EIB, in accordance with the terms of the 14 th resolution of the shareholders' meeting held on June 28, 2024 and articles L. 228-91 and seq. of the French Commercial Code (the "Tranche C Warrants"). Each Tranche C Warrant allows the EIB to subscribe for one ordinary share of the Company, at a price of €1.70, corresponding to 99% of the volume-weighted average price of the Company's ordinary shares over the last 3 trading days preceding the decision of the board of directors of the Company to issue the Tranche C Warrants. The total number of shares issuable upon exercise of the Tranche C Warrants represent circa 0.6% of the Company's outstanding share capital as at their issuance date. Tranche C will mature six years from its disbursement date and will accrue interest at a rate of 6% per annum capitalized annually and payable at maturity. The other terms of the Tranche C Warrants and prepayment events of Tranche C under the Finance Contract are as set forth in the Company's press release of April 4, 2023 and Form 6-K filed with the U.S. Securities and Exchange Commission on such date. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with 25 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN ® , its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis' headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market CLLS and on Euronext Growth ALCLS . To find out more, visit our website: www.cellectis.com Follow Cellectis on social networks @cellectis on LinkedIn and X (formerly Twitter) TALEN® is a registered trademark owned by Cellectis. Cautionary Statement This press release contains "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expect," "plan," and "will," or the negative of these and similar expressions. These forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the date of disbursement of the Tranche C and the use of the proceeds of amounts received under the Finance Contract. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with market conditions, and our ability to satisfy the conditions precedent under the Finance Contract. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2023 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC's website at www.sec.gov , as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Interim Chief Financial Officer, investors@cellectis.com Attachment 20241128_Cellectis_BEI_Tranche C_ENGLISH_PR-MBT © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Rudy Giuliani in a courtroom outburst accuses judge in assets case of being unfair, drawing a rebuke
NoneA social services agency that operates a supervised consumption site in Toronto has filed a legal challenge against recently passed Ontario legislation that will shut down several such sites and effectively prevent new ones from opening. The Neighbourhood Group Community Services agency, along with two people who use or have used supervised consumption sites, argue the legislation violates the Charter of Rights and Freedoms as well as the Constitution. They argue the law infringes on the right to life, liberty and security of the person by forcing people who use the sites to instead resort to unhealthy and unsafe consumption, which carries an increased risk of death from overdose. The challenge also argues the legislation goes against the division of powers between Ottawa and provinces, in that only the federal government can make criminal law and try to suppress what it considers a "socially undesirable practice." 10 consumption sites to close by end of March Premier Doug Ford's Progressive Conservative government has taken a hard line on supervised consumption sites in favour of an abstinence-based model for treatment. The government fast-tracked legislation that prohibits any supervised consumption sites within 200 metres of a school or daycare, and is set to close 10 sites that are within that range. Instead, the province plans to put in place 19 new "homelessness and addiction recovery treatment hubs," plus 375 highly supportive housing units at a planned cost of $378 million. Union urges Toronto to keep workers at safe injection site slated to close Ford government's opioid strategy outdated, auditor general says Ontario's auditor general found in her latest report that the province's opioid strategy is outdated and a new, comprehensive approach is needed to deal with the ongoing crisis. In the report released last week, Shelley Spence also found that more than 1,600 overdoses were reversed in 2022-23 at the sites slated to close, and no one died of an overdose at those locations in the same time frame. Under the legislation, the 10 sites have to close by March 31, 2025.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Evolv Technologies Holdings, Inc. ("Evolv Technologies" or "the Company") EVLV and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Evolv Technologies securities between August 19, 2022 and October 30, 2024 inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/EVLV. Case Details The Complaint alleges that on October 25, 2024, the Company announced that its financial statements issued between the second quarter of 2022 and the second quarter of 2024 should not be relied upon due to material misstatements impacting revenue recognition and other previously reported metrics that are a function of revenue. The Complaint adds that the Company revealed that "certain sales, including sales to one of its largest channel partners, were subject to extra-contractual terms and conditions" not shared with the Company's accounting personnel "and that certain Company personnel engaged in misconduct in connection with those transactions," and that the Company also announced that it "expects to report one or more additional material weaknesses in internal control over financial reporting," was delaying filing its upcoming quarterly report for the third quarter of 2024, and that it has "self-reported these issues" to the Division of Enforcement of the SEC. Following this news, the price of Evolv stock declined roughly 40%, from $4.10 per share on October 24, 2024, to $2.47 per share on October 25, 2024. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/EVLV. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660 . If you suffered a loss in Evolv Technologies you have until Dec. 31, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Carter's single White House term still stirs controversy after more than 40 years
Wyden legislation would mandate FCC cybersecurity rules for telecoms